BRCA2 and myelodysplastic syndrome: In addition, among 21 targets that are more significantly edited (shown in the heatmap, Fig. 2e) in LT-HSCs versus all other populations, Brcc3 or BRCA1/BRCA2 containing complex 3, has been reported to be mutated in myelodysplasia syndrome (MDS) and in de novo AML36,37.